Sign in
NVCT Stock Price, Chart, Stats & News
Nuvectis Pharma, Inc.
Save
Nuvectis Pharma, Inc. (NVCT) does not currently pay a dividend.
560.45M
Market cap
–
Current P/E
–
Forward P/E
NVCT chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -83.39% |
ROE | -131.80% |
D/E | – |
Interest coverage ratio | – |
NVCT valuation
P/E | – |
P/S | – |
P/B | 8.86x |
P/CF | -10.19x |
P/FCF | -12.38x |
P/OCF | -10.19x |
PEG | -2.78x |
EV multiple | -8.33x |
About
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases.
Similar securities
Based on sector and market capitalization
Report issue